首页> 美国卫生研究院文献>Diagnostic Pathology >Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study
【2h】

Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study

机译:基底细胞腺瘤和基底细胞腺癌之间split 1蛋白表达的转导蛋白样增强子的差异-免疫组织化学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBasal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are benign and malignant, basaloid salivary gland neoplasms, respectively. These tumors show a dual-cell proliferation of inner luminal/ductal cells and outer abluminal/myoepithelial or basal cells. The only difference between them is defined as a malignant morphology such as invasion. Recently, the nuclear expression of β-catenin and a catenin beta-1 (CTNNB1) mutation were found in BCA. Transducin-like enhancer of split 1 (TLE1) belongs to the Groucho/TLE family, and it functions in the “off” state in the Wnt/β-catenin signaling pathway. We hypothesized that if the dysregulation of the Wnt/β-catenin signaling pathway could be attributed to the tumorigenesis of BCA/BCAC, there might be differences in TLE1 expression between BCA and BCAC.
机译:背景基底细胞腺瘤(BCA)和基底细胞腺癌(BCAC)分别是良性和恶性的基底唾液腺肿瘤。这些肿瘤显示出内腔/导管细胞和外腔/肌上皮或基底细胞的双细胞增殖。它们之间的唯一区别被定义为恶性形态,例如浸润。最近,在BCA中发现了β-catenin和catenin beta-1(CTNNB1)突变的核表达。分裂1(TLE1)的转导蛋白样增强子属于Groucho / TLE家族,在Wnt /β-catenin信号传导途径中处于“关闭”状态。我们假设,如果Wnt /β-catenin信号通路的失调可归因于BCA / BCAC的肿瘤发生,则BCA和BCAC之间的TLE1表达可能存在差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号